Want to see PPBT full AI Analyst Report?
PPBT Stock Chart & Stats
$1.66
$0.01(0.70%)
At close: 4:00 PM EDT
$1.66
$0.01(0.70%)
Day’s Range― - ―
52-Week Range$1.16 - $14.89
Previous Close$1.45
Volume11.51K
Average Volume (3M)60.88K
Market Cap
$10.72M
Enterprise Value-$4.20
Total Cash (Recent Filing)$6.11M
Total Debt (Recent Filing)$134.00K
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Nov 13, 2026EPS Estimate
-2.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.22
Shares Outstanding1,620,982
10 Day Avg. Volume31,390
30 Day Avg. Volume60,881
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)3.25
Price to Sales (P/S)0.00
P/FCF Ratio-5.69
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$17.00Price Target Upside924.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-5.31
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Differentiated Immuno-Oncology PlatformThe tri-specific, masked design targets major limitations of existing solid-tumor T-cell engagers. If sustained in clinical testing, tumor-selective activation and dual immune-cell engagement could provide a meaningful competitive distinction.
Encouraging Preclinical Efficacy And SafetyData across patient-derived tumors and toxicology studies support continued development of IM1240. Evidence of efficacy combined with reduced cytokine release and improved exposure may increase the probability of attracting partners or advancing into trials.
Low Financial LeverageMinimal debt limits refinancing and solvency risk while the company develops its pipeline. Although the balance sheet is weakening through losses, low leverage preserves flexibility relative to a similarly cash-burning biotech carrying substantial borrowings.
Bears Say
Minimal Revenue And Persistent LossesThe company remains pre-commercial, with no stable product revenue offsetting substantial R&D spending. Continued losses reduce financial resilience and mean future value depends heavily on successful clinical development, licensing, or other funding sources.
Ongoing Cash Burn And Funding DependenceNegative cash generation means the business is not self-sustaining and will likely require financing, partnerships, or milestone proceeds before commercialization. Future capital needs could create dilution or constrain the pace and scope of clinical development.
Clinical And Execution RiskThe lead program remains preclinical, leaving several years of regulatory, manufacturing, recruitment, and trial execution risk before human proof-of-concept. Delays or disappointing safety and efficacy results could materially weaken the pipeline’s partnering prospects.
Purple Biotech News
PPBT FAQ
What was Purple Biotech’s price range in the past 12 months?
Purple Biotech lowest stock price was $1.16 and its highest was $14.89 in the past 12 months.
What is Purple Biotech’s market cap?
Purple Biotech’s market cap is $10.72M.
When is Purple Biotech’s upcoming earnings report date?
Purple Biotech’s upcoming earnings report date is Nov 13, 2026 which is in 71 days.
How were Purple Biotech’s earnings last quarter?
Purple Biotech released its earnings results on Aug 07, 2026. The company reported -$0.41 earnings per share for the quarter, missing the consensus estimate of $0.35 by -$0.76.
Is Purple Biotech overvalued?
According to Wall Street analysts Purple Biotech’s price is currently Undervalued.
Does Purple Biotech pay dividends?
Purple Biotech does not currently pay dividends.
What is Purple Biotech’s EPS estimate?
Purple Biotech’s EPS estimate is -2.88.
How many shares outstanding does Purple Biotech have?
Purple Biotech has 1,620,982 shares outstanding.
What happened to Purple Biotech’s price movement after its last earnings report?
Purple Biotech reported an EPS of -$0.41 in its last earnings report, missing expectations of $0.35. Following the earnings report the stock price went up 1.418%.
Which hedge fund is a major shareholder of Purple Biotech?
Currently, no hedge funds are holding shares in PPBT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Purple Biotech
Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer. NT219: A small molecule compound that targets insulin receptor substrate 1 and 2 (IRS1/2) as well as signal transducer and activator of transcription (STAT) pathways. NT219 is currently in Phase 1/2 clinical studies for the treatment of recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck. The company was formerly known as Kitov Pharma Ltd until its rebranding to Purple Biotech Ltd. in December 2020.
PPBT Stock 12 Month Forecast
Average Price Target
$17.00
▲(924.10% Upside)
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
1.76% Other Institutional Investors
98.24% Public Companies and
Individual Investors